Monday, November 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· March 10, 2026

Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount

View original at finance.yahoo.com
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount This article first appeared on GuruFocus. Introduction: At $24.50, what you're really getting with Catalyst Pharmaceuticals Inc…
Opening lines of the source · Yahoo Finance · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hetero litigation expected to conclude sometime in 2026

    80% confidence
  • FIRDAPSE patent protection extends through February 2035

    80% confidence
  • Estimated 3,000-4,000 US patients with Lambert-Eaton Myasthenic Syndrome

    80% confidence
  • There are approximately 15,000 patients in the US with Duchenne Muscular Dystrophy

    80% confidence
  • Current R&D spending is about 5-8% of revenue

    80% confidence

Cited in these Via News reports

Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount: Source | Via News | finance.via.news